Thymosin Alpha-1

Thymosin Alpha-1

Thymosin Alpha-1

Thymosin alpha 1 (TA-1) he 28-amino acid peptide i hana ʻia i loko o ka thymus.

Pane wikiwiki

Thymosin Alpha-1 is a biologically active thymic synthetic peptide with excellent immune regulation performance. It activates T lymphocyte proliferation, enhances cellular immune function, improves body resistance against pathogens, and serves as core material for immunology and clinical biomedical research.

SKU: 198889 Māhele:
Kaʻana like i kāu aloha

Thymosin alpha 1 (TA-1) he 28-amino acid peptide i hoʻohui ʻia i loko o ka koumus. Ke lawelawe nei ma ke ʻano he immunomodulator endogenous, hoonui ia ʻO ke kino i hoʻopaʻa ʻia e ke kelepona T nā pane; ʻO nā mīkini kikoʻī e pili ana i ka ʻokoʻa a me ka hoʻomaʻamaʻa ʻana o ke kelepona T nā pūnaʻi progenitor, hooikaika ana o nā pūpū dendritic a me nā pūnaewele pepehi kanaka maoli, me nā ʻano ʻano like ʻole o ka maʻi ʻana o ka cytokine-mediated.

Mai kona ʻike ʻana, Ua hoʻokumu ʻia ka ʻike piha ʻana o Thymosin alpha 1's immune-enhancing properties.

Kaʻina

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

Helu CAS

62304-98-7

ʻĀpana Molekala

C129H215N33O55

Kaumaha Molekala

3108.28

Noi'i o Thymosin Alpha-1

1.ʻO nā hana a me nā hana Immunomodulatory

E like me ka pleiotropic immunomodulatory mole, ʻO ka hana pharmacological mua o thymosin alpha-1 ka hoʻihoʻi a me ka hoʻonui ʻana i ka hana immune – ʻO ka immunodeficiency kahi mokuʻāina nui e hoʻoponopono ai.

Ke hana nei ma ke ano he agonist no Loaʻa like ʻole (TLR) 9 a me TLR-2 i loko o nā pūnaewele dendritic (ʻoihana nā pūnaewele hōʻike antigen), Thymosin alpha 1 hoʻoulu i ka adaptive nā pane immune; viral, bacteria, ʻO nā maʻi fungal a me ka maʻi kanesa nā mea e hiki ai ke hoʻokō i kēia mau pane.

Hoʻonui ʻia ka palekana humoral. Hoʻonui i nā pae o nā cytokines he nui (IL-2, IL-10, IL-12, IFN he mau kumu hoʻohālike) ʻO kekahi hopena i kākau maikaʻi ʻia.

ʻO ka hoʻoulu ʻana i ka hana antibody T cell-dependent ke kumu i hāʻawi pinepine ʻia no kāna mau waiwai adjuvant.

Nā hana olaola ākea ākea, antitumor i waena o lākou, ke noiʻi ʻia nei i kēia manawa.

2.Nā noi lāʻau lapaʻau a me ka hiki ke hoʻōla
(1)Lapaʻau ʻana i nā maʻi maʻi maʻi

Ua loiloi nā hoʻokolohua lapaʻau i ka palekana a me ka pono o thymosin alpha 1 ma ka hoomau ka maʻi hepa B(HBV) nā maʻi. ʻO ka hoʻoikaika ʻana i ka hoʻomaʻemaʻe viral a me ka hoʻihoʻi ʻana i ka hana o ke ake ma hope mai kahi pane kikoʻī T-cell kūʻē iā HBV.

ʻO ka hui pū ʻana me ka interferon pegylated maikaʻi ka maʻi hepa C; thymosin pono'ī a i hui pū me interferon, ke noho nei he koho lapaʻau kūpono.

Ua hoʻokuʻu aku nā antivirals hana pololei i ka thymosin mai ka lāʻau lapaʻau mua, akā, nā hopena hoʻoikaika kino o ka thymosin alpha 1 e hoʻomau i ka pili kino.

(2)Kāohi i ka ulu ʻana o ke koko

Ua hōʻike ʻia nā noiʻi he nui i nā noi hoʻohiki no thymosin alpha-1 i nā maʻi me ka metastatic melanoma, ka maʻi maʻi poʻo a me ka ʻāʻī, ka maʻi ʻaʻai māmā, ka maʻi ʻaʻai umauma, a hepatocellular carcinoma.

Hoʻohana ʻia e like me ka adjunctive therapy, ʻōlelo ia i ka immunosuppression i hoʻokomo ʻia i ka chemotherapy, immunodeficiency mua, a me nā ʻano like ʻole o nā ʻano immunosuppressive.

ʻO ka hoʻohui ʻana i ka thymosin alpha-1 me ka chemotherapy a i ʻole ka radiotherapy i hōʻike i ka hoʻomaikaʻi ʻana i nā helu ola; ʻaʻai maʻi ʻaʻai māmā liʻiliʻi ʻole (ʻo ka hapa nui o nā maʻi kanesa āpau) he kumu hoohalike, ʻo ka chemosensitivity maikaʻi ʻole kekahi o nā pilikia nui o kēia maʻi.

(3)Ka mālama ʻana i ka Sepsis

Hoʻohana ʻia ʻo Thymosin alpha-1 i ka mālama ʻana i ka pae immunosuppressive o maʻi maʻi.

Hoʻihoʻi hou i ka helu a me ka hana o nā lymphocytes – ʻO nā pūnaewele T ke kiko kiko – manaʻo ʻia e hoʻohuli i ke kūlana o ka maʻi maʻi maʻi.

Hoʻomaʻemaʻe i ka maʻi mua, e hoemi ana i na ma'i lua mahope, a ʻo ka hoʻomaikaʻi ʻana i ka prognosis he mau pōmaikaʻi i hōʻike ʻia o kēia therapy.

Ua kākoʻo nā haʻawina lāʻau lapaʻau i nā noi hoʻohiki, wale a hui pū me nā lāʻau ʻē aʻe.

(4)Ma ke ano he Vaccine Adjuvant

ʻO kahi adjuvant kano kahi e hōʻike ai ʻo thymosin alpha-1 i kekahi o kāna mau hopena kūlike a waiwai.

He mea nui ka pane ʻana o ka pale kino no ka pale ʻana a i ʻole ka mālama ʻana i nā maʻi he nui; maʻi maʻi maʻi, AIDS, a me ka maʻi kanesa lapaʻau nā lāʻau lapaʻau he mau laʻana kaulana.

Nā lāʻau lapaʻau influenza (oi aku no ka poe elemakule) ke aʻo ʻia nei me ka hoʻohana ʻana i kēia adjuvant, me nā hopena lapaʻau maikaʻi.

(5)ʻO ka lāʻau lapaʻau hui no ka maʻi HIV me nā lāʻau ʻē aʻe

Hoʻohui ʻia ʻo thymosin alpha-1 me interferon-α1 a zidovudine hoʻonui i ka hana immune.

CD4+ piʻi ka helu, Ke emi nei ka viral load a hoʻomaikaʻi ʻia ke kūlana o ka maʻi HIV.

ʻO ka hoʻohana lōʻihi ʻana o ka thymosin alpha-1 kiʻekiʻe he ala immunomodulatory koʻikoʻi.

Noho ʻo Thymosin alpha-1 i kahi immunomodulator pleiotropic maoli me ka hiki ke hoʻōla nui.

COA

HPLC

MS

(1).Poo, J. L.; SANchez-Avila, F.; Kershenobich, D.; ʻO García-Samper, X.; ʻO Gongora, J.; Uribe, M. ʻO ka hui ʻekolu o thymalfasin, ʻO ka peginterferon alfa-2a a me ka ribavirin i nā maʻi me ka maʻi hepa C maʻi i hāʻule mua i ka interferon a me ka ribavirin lapaʻau.: 24ʻO nā hopena manawa pōkole o ka noiʻi hoʻokele J. Gastroenterol. Hepatol. 2004.

(2).Romani, L.; ʻO Bisto, F.; Gaziano, R.; He ipukukui, S.; Montagnoli, C.; Perruccio, K.; ʻO ka lua, L.; Nānā, S.; Velardi, A.; ʻO Rasi, ʻO G.; o Francesco, P.; hale kaʻa, E. Thymosin a 1 hoʻolaʻa i nā cell dendritic no ka antifungal Th1 kū'ē ma o Toll-like receptor signaling Koko 2004,4232-4239.

(3).Tuthill, C.; Rios, I.; ʻulaʻula, A.; Nā lumi ʻaʻahu, R. Ke hoʻomau nei ʻo Thymosin α1 e hōʻike i ka ʻōlelo hoʻohiki ma ke ʻano he mea hoʻonui no ka pane ʻana i ke kano ʻO Ann. N.Y.. Acad. ʻO Sci. 2012,21-27.

(4).Naylor, P. H.; Nā huinahā, K.; hale kaʻa, E.; ʻO Rasi, ʻO G.; Ua loaʻa, J. Ua ʻōlelo ʻo W. Immunopharmacology o Thymosin α1 a me Cytokine Synergy ʻO Ann. N.Y.. Acad. ʻO Sci. 2007,235-244.

(5).Sherman, K. E. Thymosin a 1 no ka mālama ʻana i ka maʻi hepatitis C: olelo hoopomaikai ʻO Ann. N.Y.. Acad. ʻO Sci. 2010,136-140.

(6).Eckert, K.; ʻO Schmitt, M.; Garbin, F.; hoopunipuni, U.; Maurer, H. R. Nā hopena Thymosin α1, in vitro, ma ka lymphokine-activated killer cell mai nā maʻi me nā immunodeficiencies mua: Nā hualoaʻa mua Int. J. Immunopharmacol 1994,1019-1025.

(7).Constantines, C.; Bellet, M. M.; Pariano, M.; Renga, ʻO G.; Stincardini, C.; Goldstein, A. L.; hale kaʻa, E.; Romani, L. ʻO kahi loiloi hou o Thymosin Alpha1 i ka maʻi maʻi maʻi Imua. ʻO Oncol. 2019.

(8).Li, C.; ʻO Bo, L.; Liu, Q.; Jin, F. ʻO Thymosin alpha1 e pili ana i ka immunomodulatory therapy no ka sepsis: he loiloi hoʻonohonoho a me ka meta-analysis Int. J. Hoʻopili. Dis. 2015,90-96.

(9).Panatto, D.; Hoalohaloha, D.; E ʻae, P. L.; Nā lumi ʻaʻahu, R.; Rosa, A. D.; Gasparini, R. Ka pono o ka thymosin alpha-1 (ʻO Zadaxin) ma ke ʻano he co-adjuvant i nā lāʻau lapaʻau influenza: he loiloi. Nūpepa o ka Lapaʻau Kāohi a me ka Maʻemaʻe. J. Mamua. Me. ʻO Hyg. 2015.

(10).ʻO Matteucci, C.; ʻO Grelli, S.; poe pana kea, E.; Minuke, A.; Argaw-Denboba, A.; Nā kiko, B.; Sinibaldi-Vallebona, P.; Pin, C. F.; Mastiff, A.; hale kaʻa, E. Thymosin Alpha 1 a me HIV-1: Nā Kūlana Hou a me nā Manaʻo o ka wā e hiki mai ana Microbiol e hiki mai ana. 2017,141-155.

kikoʻī

10 mg, 5 mg

Home Huli Whatsapp Nā lawelawe Huahana